| Line | All comers | Risk group |
|---|
| Screening, prevention and diagnosis | 1 | 1 |
| Early / localised | 1 | · |
| Locally advanced | 1 | · |
| Advanced, first line | 1 | · |
Screening, prevention and diagnosis
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|
| All comers | Prevention | Tobacco and betel quid cessation, alcohol reduction, treatment of premalignant patches. | | | 32 |
| Risk group | Screening in high-risk populations | Visual oral examination by trained workers reduced mouth cancer deaths in the Kerala trial; opportunistic examination by dentists elsewhere. | | | - |
Early / localised
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|
| All comers | Early disease | Wide excision with elective neck dissection when depth of invasion exceeds about 3 to 4 mm; sentinel node biopsy in selected cases. | | | - |
Locally advanced
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|
| All comers | Locally advanced disease | Resection with neck dissection and free-flap reconstruction, then postoperative radiotherapy, or cisplatin chemoradiation for positive margins or extranodal extension. | | | 93 |
Advanced, first line
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|
| All comers | Recurrent or metastatic | Pembrolizumab with or without chemotherapy (KEYNOTE-048); low-cost metronomic methotrexate and celecoxib where access is limited. | | | 98 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.